141 related articles for article (PubMed ID: 15886706)
21. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
Neuber K; Reinhold U; Deutschmann A; Pföhler C; Mohr P; Pichlmeier U; Baumgart J; Hauschild A
Melanoma Res; 2003 Feb; 13(1):81-5. PubMed ID: 12569289
[TBL] [Abstract][Full Text] [Related]
22. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study.
Spieth K; Kaufmann R; Gille J
Cancer Chemother Pharmacol; 2003 Nov; 52(5):377-82. PubMed ID: 12879280
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study.
Wick W; Hermisson M; Kortmann RD; Küker WM; Duffner F; Dichgans J; Bamberg M; Weller M
J Neurooncol; 2002 Sep; 59(2):151-5. PubMed ID: 12241108
[TBL] [Abstract][Full Text] [Related]
24. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Thigpen T
Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
[TBL] [Abstract][Full Text] [Related]
25. Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Yen Y; Chow W; Leong L; Margolin K; Morgan R; Raschko J; Shibata S; Somlo G; Twardowski P; Frankel P; Longmate J; Synold T; Newman EM; Lenz HJ; Gandara D; Doroshow JH
Cancer Chemother Pharmacol; 2002 Nov; 50(5):353-9. PubMed ID: 12439592
[TBL] [Abstract][Full Text] [Related]
26. An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Awada A; Campone M; Varga A; Aftimos P; Frenel JS; Bahleda R; Gombos A; Bourbouloux E; Soria JC
Anticancer Drugs; 2016 Apr; 27(4):342-8. PubMed ID: 26796987
[TBL] [Abstract][Full Text] [Related]
27. Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Rachamalla R; Malamud S; Grossbard ML; Mathew S; Dietrich M; Kozuch P
Anticancer Drugs; 2004 Mar; 15(3):211-7. PubMed ID: 15014353
[TBL] [Abstract][Full Text] [Related]
28. Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Yuan Y; Cohen DJ; Love E; Yaw M; Levinson B; Nicol SJ; Hochster HS
Cancer Chemother Pharmacol; 2011 Aug; 68(2):371-8. PubMed ID: 20978761
[TBL] [Abstract][Full Text] [Related]
29. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma.
Schmidt-Hieber M; Schmittel A; Thiel E; Keilholz U
Melanoma Res; 2004 Dec; 14(6):439-42. PubMed ID: 15577312
[TBL] [Abstract][Full Text] [Related]
31. Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors.
Infante JR; Hollebecque A; Postel-Vinay S; Bauer TM; Blackwood EM; Evangelista M; Mahrus S; Peale FV; Lu X; Sahasranaman S; Zhu R; Chen Y; Ding X; Murray ER; Schutzman JL; Lauchle JO; Soria JC; LoRusso PM
Clin Cancer Res; 2017 May; 23(10):2423-2432. PubMed ID: 27815358
[No Abstract] [Full Text] [Related]
32. Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
Soo RA; Lim HL; Wang LZ; Lee HS; Millward MJ; Tok LT; Lee SC; Lehnert M; Goh BC
Cancer Chemother Pharmacol; 2003 Aug; 52(2):153-8. PubMed ID: 12750842
[TBL] [Abstract][Full Text] [Related]
33. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
34. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo.
Neuber K; tom Dieck A; Blödorn-Schlicht N; Itschert G; Karnbach C
Melanoma Res; 1999 Apr; 9(2):125-32. PubMed ID: 10380934
[TBL] [Abstract][Full Text] [Related]
35. A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors.
Schelman W; Morgan-Meadows S; Bailey H; Holen K; Thomas JP; Eickhoff J; Brandon H; Oliver K; Alberti D; Wilding G
Cancer Chemother Pharmacol; 2008 Sep; 62(4):727-33. PubMed ID: 18172649
[TBL] [Abstract][Full Text] [Related]
36. Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Shoji H; Morizane C; Sakamoto Y; Kondo S; Ueno H; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Ikeda M; Okusaka T
Jpn J Clin Oncol; 2016 Feb; 46(2):132-7. PubMed ID: 26685318
[TBL] [Abstract][Full Text] [Related]
37. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies.
Scheulen ME; Hilger RA; Oberhoff C; Casper J; Freund M; Josten KM; Bornhäuser M; Ehninger G; Berdel WE; Baumgart J; Harstrick A; Bojko P; Wolf HH; Schindler AE; Seeber S
Clin Cancer Res; 2000 Nov; 6(11):4209-16. PubMed ID: 11106234
[TBL] [Abstract][Full Text] [Related]
38. Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer.
Barlow C; Nystrom M; Oesterling C; Fennell D; Ismay J; Gallagher C
Br J Cancer; 2004 Apr; 90(7):1318-22. PubMed ID: 15054448
[TBL] [Abstract][Full Text] [Related]
39. A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Adjei AA; Croghan GA; Erlichman C; Marks RS; Reid JM; Sloan JA; Pitot HC; Alberts SR; Goldberg RM; Hanson LJ; Bruzek LM; Atherton P; Thibault A; Palmer PA; Kaufmann SH
Clin Cancer Res; 2003 Jul; 9(7):2520-6. PubMed ID: 12855626
[TBL] [Abstract][Full Text] [Related]
40. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
Hensley ML; Dizon D; Derosa F; Venkatraman E; Sabbatini P; Chi DS; Dupont J; Colevas AD; Spriggs D; Aghajanian C
Invest New Drugs; 2007 Aug; 25(4):335-41. PubMed ID: 17364235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]